The therapeutic use of Surgestone (Promegestone), a progestin, is applied in addressing core domains of women's hormonal health, focusing on providing supportive symptomatic relief. The medication is commonly used to manage conditions presenting with systemic or localized discomfort.

The primary therapeutic areas involve assisting with support for the uterine lining in Menopausal Hormone Therapy (MHT), applied in addressing significant cyclical discomfort like painful periods and breast tenderness, and supporting menstrual cycle regulation for conditions such as Premenstrual Syndrome (PMS).

In the scenario of MHT, its key benefit is to provide support to help manage the state of the uterine environment, contributing to reducing the risk of Endometrial Hyperplasia. For premenopausal women, it is relevant for easing symptoms that interfere with daily functioning, contributing to improved comfort during periods of heightened symptoms.

---

Quick Fact: Cyclical Discomfort Support

Surgestone is relevant for easing symptoms related to physical discomfort that become more disruptive during flare-ups, and is applied across domains where additional symptomatic support is needed.

Regulatory References

1. Health Canada Product Monograph for a Progestin

The eligibility for Surgestone (Promegestone) is strictly defined by regulatory authorities to ensure safe use, focusing primarily on adult women. Official documents establish several populations who are strictly prohibited from using the medicine (contraindications) and others who require special caution.

Populations Who Must Not Use Surgestone (Contraindicated)

Surgestone is contraindicated and must not be used by individuals with:

• Active or a history of thromboembolic disorders (e.g., Deep Vein Thrombosis, Pulmonary Embolism, Stroke).
• Known or suspected hormone-dependent malignant neoplasia (e.g., breast or genital tract cancer).
• Severe hepatic impairment or active liver disease.
• Undiagnosed abnormal genital bleeding (until malignancy is excluded).
• Known or suspected pregnancy.

Age and Physiological Status Rules

Population Category	Official Eligibility Status
Pediatric Population	Use is not established and not recommended.
Lactation/Breastfeeding	Use is not recommended (due to excretion into human milk).

Conditional Use (Requires Monitoring)

Use is permitted only with close medical monitoring in patients with a history of severe depression, diabetes mellitus (due to potential impact on glucose tolerance), or hypertension, as specified in the official labeling.

Interactions with other medicines and products

The official regulatory profile for Promegestone (Surgestone) is structured around a specific caution related to the duration of exposure rather than co-administration with other substances.

---

Drug-Drug and Metabolic Interactions

No specific medicinal product categories, individual medicines, herbal products, or foods are explicitly cited in regulatory product information as having required co-administration restrictions or timing-based rules with Promegestone. The official labeling does not include statements detailing interactions related to metabolic enzymes, such as the CYP system, or drug transporters. Therefore, the documented interaction map for Surgestone is not primarily defined by traditional pharmacokinetic drug-drug conflicts.

---

Duration-Dependent Pharmacological Risk

The most significant item in the regulatory profile is a specific caution tied to the length of treatment. Epidemiological data reviewed by national health authorities confirm that prolonged use of the drug, typically defined as continuous exposure for one year or longer, is officially associated with an increased incidence of Intracranial Meningioma. This finding classifies the continuous administration of Promegestone as a duration-dependent risk condition. This regulatory constraint dictates that the official risk framework focuses on the condition of long-term exposure as the key determinant in the overall interaction profile.

Receptor-Mediated Genomic Signaling

Surgestone functions as a full agonist by selectively binding to Progesterone Receptors (PRs) in target cells. This molecular interaction initiates a genomic signaling cascade. The activated drug-receptor complex translocates to the cell nucleus, where it binds to specific DNA sequences, thereby altering the transcription of target genes. This action modifies the profile of proteins synthesized by the cell, initiating the mechanism that influences the subsequent behavior and growth of hormone-sensitive tissues.

---

Endocrine System and Tissue State Modulation

Following genomic signaling, the drug modulates the reproductive endocrine system. By altering gene expression within the uterine lining, Surgestone induces a significant shift in tissue state, establishing a secretory and differentiated morphology rather than a proliferative one. Furthermore, the drug exerts a central action by influencing the hypothalamic-pituitary-ovarian axis, which contributes to broader endocrine regulation. This modulation results in a systemic shift in the reproductive system's functional status, consistent with the drug's known physiological effects.

Official Administration Guidelines

Surgestone, whose active ingredient is Promegestone, is administered exclusively via the oral route as a tablet. Administration protocols follow the principle of prescribing the minimum effective dose for the shortest duration necessary.

Dosing and Scheduling Patterns

Official strengths of the oral tablet include 0.125 mg, 0.250 mg, and 0.500 mg, allowing for required dose flexibility. The medicine is typically integrated into treatment schedules following one of two patterns:

• Cyclic Regimen: Administration for a defined, limited number of days per course (e.g., 10 days per cycle) is a standard approach, particularly when used for endometrial support in non-hysterectomized women.
• Continuous Regimen: A consistent, once-daily schedule is employed for other conditions. For instance, a 0.5 mg dose per day is a reference point for certain daily hormonal modulation regimens.

Procedural and Duration Constraints

Usage is characterized by a constraint on duration; continuous treatment is discouraged, and the overall course should be as brief as clinically feasible. The necessity for continued use must be professionally re-evaluated regularly, with assessment recommended at least once a year. No specific high-level dose adjustments for patients with renal or hepatic impairment are detailed in official summary documents.

Surgestone: Recent Clinical Evidence

The research evidence for Surgestone (Promegestone) was evaluated in randomized controlled trials (RCTs), systematic reviews, and large-scale observational studies. This evidence primarily focuses on its role as a progestin in menopausal hormone therapy (MHT) and cycle regulation.

---

Evidence for Hormone Therapy and Cycle Support

For MHT, studies examined populations of postmenopausal women with an intact uterus who were receiving estrogen replacement. Research reports that when a progestin, such as Promegestone, is used in combination with estrogen, data show patterns related to changes in the uterine lining. This finding is consistent across the progestin class.

In the context of cycle regulation, research has examined Promegestone's role in conditions related to temporary physiological imbalance in premenopausal women. Controlled trials monitored hormonal biomarker shifts and evaluated patient-reported outcomes describing perceived discomfort related to cyclical symptoms. Research describes patterns observed in the studies related to its effect on the cycle, though findings were mixed when compared to placebo in some specific cohorts.

---

Limitations and Ongoing Research

Evidence is limited in several areas. Follow-up durations were limited to intermediate terms in many early trials, meaning long-term effects for specific formulations are not fully established. Comparative evidence is lacking between Promegestone and all other individual progestins across every relevant hormonal outcome.

One area of recent research focus is on the long-term use of progestogens (as a class). A national case-control study reported that prolonged use of specific progestogens, including Promegestone, was associated with an increased risk of intracranial meningioma. This finding highlights the need for ongoing research and confirms that evidence for certain groups remains insufficient to draw definitive long-term safety conclusions across all formulations and doses. Research is ongoing to provide context but not individual predictions regarding the use of progestins.

Key Studies & References Management of Endometrial Hyperplasia - Green-top Guideline No. 67

Common questions about Surgestone (FAQ)

Q: Is Surgestone the same kind of medication as other drugs used for the same purpose?

Surgestone's active ingredient is Promegestone, which is classified as a synthetic progestogen, or progestin. This means it belongs to the general class of medications designed to mimic the effects of the body's natural progesterone. Official documents indicate that the medicine's main purpose is to provide specific progestogenic support to the endocrine system.

Q: Is Surgestone used by men, or is it only prescribed for women?

Regulatory indications for Surgestone are established specifically for use in adult women for hormone-related conditions. Official documentation does not establish use or safety guidelines for men or other populations. Any use outside of the established regulatory indications is not officially documented.

Q: How long does Surgestone stay in the body after the last use?

After ingestion, Surgestone is rapidly processed into its main active compound, Trimegestone. This active compound has an elimination half-life typically ranging from approximately 14 to 16 hours. This timeframe indicates the general rate at which the substance is cleared from the body.

Q: Is it safe to drive or operate machinery while taking Surgestone?

Official product information indicates that the medication may have neurosteroid activity, which can potentially affect the central nervous system. Due to this potential for effects on attention or confusion, patients are advised to exercise caution when operating machinery or driving until they understand how the medication affects them.

Q: What kind of research exists regarding Surgestone and pregnancy risk?

Official regulatory documents note that the medication is strictly contraindicated in cases of known or suspected pregnancy. This is due to safety concerns identified in non-clinical studies that have reported effects on the fetus.

Q: Can users with a history of heart problems be prescribed Surgestone?

Surgestone is strictly contraindicated for individuals who have a history of thromboembolic disorders, such as blood clots (Deep Vein Thrombosis or Pulmonary Embolism). For patients with other pre-existing heart problems, official guidance specifies that use is permitted only under close medical monitoring.

Q: What happens if I miss a dose of Surgestone?

General regulatory guidance suggests taking the missed dose if recalled soon after the scheduled time, but skipping it if it is nearly time for the next dose. Official information emphasizes that double doses are not permitted to compensate for a forgotten one. This type of procedural information should be confirmed with a healthcare professional.

Q: Why are people talking about Surgestone causing stomach upset?

The official product information lists nausea as one of the commonly reported adverse reactions associated with Surgestone. Nausea is a common symptom that can contribute to what users often describe as general stomach upset.

Q: Does taking Surgestone affect sleep patterns?

The medication has been found to exert neurosteroid activity, meaning it can influence the central nervous system and brain function. This type of effect has been noted to influence a user's normal sleep patterns.

Q: Can elderly patients use Surgestone safely?

Surgestone is intended for use in adult women. Official documents do not provide specific high-level dose adjustments detailed for geriatric patients. As with all populations, use is subject to regular clinical monitoring and re-evaluation to ensure continued appropriateness.

Q: What should a user do if they experience a severe side effect while using Surgestone?

Patients are advised to seek immediate medical attention if they experience any signs of serious adverse reactions. This includes symptoms related to blood clots (thromboembolic events), severe liver dysfunction, or new neurological symptoms.

Q: What does the latest research suggest about the effectiveness of Surgestone?

Studies have examined the medication's role in menopausal hormone therapy by showing patterns of change in the uterine lining and note patterns related to its use in cycle regulation by monitoring shifts in hormonal biomarkers. However, official information notes that findings were mixed in some specific patient cohorts.

Storage Requirements

Surgestone (Promegestone) must be stored at Controlled Room Temperature, which is typically maintained between 20 C to 25 C (68 F to 77 F). The medication must be kept in its original container and shielded from excessive moisture and light to protect the chemical stability of the tablets. Storage in areas of excessive heat, or environments where the tablets could freeze or be refrigerated, is prohibited. As a safety requirement, the medicine must be kept safely out of the sight and reach of children at all times.

Disposal Instructions

Expired or unused Surgestone tablets must be disposed of in accordance with local and national regulatory requirements. It is essential not to dispose of this medicine through general household trash or by flushing it down a toilet or sink, unless specifically instructed by a formalized drug take-back program. Disposal should follow established pharmaceutical waste protocols.